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SUMMARY
JAK2V617F mutation is a well-recognized feature in
most Ph-negative myeloproliferative neoplasms (MPNs).  An
activated bone marrow (BM) angiogenesis has been estab-
lished in these disorders as well. Consequently, the rational
question is to ascertain a possible relation among JAK2 mu-
tation, morphological features and angiogenesis in MPNs
bone marrow.
Aim: To assess bone marrow microvessel density
(MVD), bone marrow cellularity and fibrosis in newly diag-
nosed patients with BCR-ABL-negative MPNs, and define
a correlation between the degree of angiogenesis in the bone
marrow and JAK2V617F mutant allele burden.
Methods: JAK2 mutational burden was determined by
RT-PCR, BM angiogenesis was defined by MVDassessment
using anti-CD34 for BM endothelium staining. The BM fi-
brosis was evaluated according to the Hanover system. The
statistical analysis was performed with SPSS 17.0 software.
52 patients with newly diagnosed MPN were included in the
study.
Results: The distribution of the mutational burden
was as follows: 26 patients with polycythaemia vera (PV),
16 patients with primary myelofibrosis (PMF) and 10 patients
with essential thrombocythaemia (ET).  In patients with PV
the homozygosity was found prevalent in frequency whereas
in PMF and ET the heterozygous variants were dominant.
In all patients a significant positive correlations between
JAK2V617F and BM MVD (r=0.306, p<0.002) and between
MVD and fibrosis, (r=0.523, p<0.0001), was found.JAK2 cor-
related positively but borderline with fibrosis. The MVD and
JAK2 burden were found in significant negative correlation
with the BM cellularity (r=-0.405; p<0.002 and r=-0.431,
p<0.0001, resp.).
Conclusions: The significant correlation between
JAK2V617F, BM angiogenic activity and the fibrosis marks
out the JAK2 allele burden as a feasible parameter with prog-
nostic significance for evolution and progression of MPN.
Key words: JAK2V617F mutation, angiogenesis, my-
eloproliferative neoplasm, polycythaemiavera (PV), essential
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In 2005 four separate groups using different models
and measurement techniques (Baxer et al., James et al.,
Kralovics et al. and Levin et al.), reported the presence of
a novel somatic point mutation in the conserved auto-
inhibitorypseudokinase domain of the gene coding for the
Janus kinase 2 (JAK2) protein in patients with classic
MPNs. The mutation is located on exon 14 of the gene and
was noted to cause a valine-to-phenylalanine substitution
at amino acid position 617. The loss of JAK2 autoinhibition
caused by JAK2V617Fmutation results in constitutive ac-
tivation of the kinase and in recruitment and phosphoryla-
tion of substrate molecules including downstream signaling
pathways JAK-STAT, PI3K/AKT, MAPK/ERK [1, 2]. In hu-
mans JAK2V617F mutation presents at the stem cells level
and is present in hematopoietic stem cell progenitor [3].
The angiogenesis (new blood vessel formation) is a
key requirement for tumor growth and spread (Folkman
1995). Vascular endothelial growth factor (VEGF) has a
rate-limiting role in promoting tumor angiogenesis and ex-
erts its effects by binding to its tyrosin kinase receptors:
VEGF-R1 and VEGF-R2 [4]. Several studies suggestthe role
of angiogenesis in hematological malignancies such as
acute and chronic leukemia, lymphoma and multiple my-
eloma. The available data on angiogenesis and VEGF ex-
pression in the bone marrow of patients with BCR-ABL-
negative myeloproliferative neoplasms (MPN) reveal that
micro vessel density (MVD) is increased, especially in pri-
mary myelofibrosis (PMF), and that increased angiogenesis
might inversely correlate with survival [5]. Our previous
data from the analysis of bone marrow pathology and ang-
iogenesis in patients with Ph-negative MPN shows in-
creased angiogenic activity, especially in PMF [6].
The correlation between JAK2V617F mutational sta-
tus and angiogenesis in the bone marrow in patients with
MPNs has been addressed in few publications with contra-
dictory results [7, 8, 9]. Since, the increased activity of the
VEGF-pathway can serve as a treatment target, additional
studies on the relation between mutational status and de-
gree of angiogenesis are further required.
The aim of our study was to assess bone marrow
MVD, bone marrow cellularity and fibrosis in newly diag-
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nosed patients with BCR-ABL-negative MPNs and to de-
fine a correlation between the degree of angiogenesis in
the bone marrow and JAK2V617F mutant allele burden.
PATIENTS AND METHODS
Aprospectivestudy was performed according to the
regulations of the local ethics committee. We included52
patients with newly diagnosed and previously untreated
MPNs. Bone marrow biopsies were analyzed for the extent
of angiogenesis. Bone marrow samples were fixed in buff-
ered neutral formalin for 12 - 48 hours.  Slides were stained
with Hematoxyline and Eosin and immunohistochemically
for the evaluation of endothelial cells with FLEX Mono-
clonal Mouse Anti-Human CD34 Class II, Clone QBend 10
(DAKO). Visualization system was Envision High pH (Link)
(Code K8000). Sections were examined for bone marrow
MVD atx400 magnification. Five hot spot areas (areas of
highest neovascularization) in CD34 stained sections were
selected and the mean number of microvessels was meas-
ured. The degree of bone marrow fibrosis was established
according to the Hannover system.
Analysis of JAK2 V617F mutation was performed
by Polymerase Chain Reaction (PCR). Peripheral blood
mononuclear cells were separated after red blood cells de-
struction with a lysis buffer (155 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA) (Silva et al., 2002) [10]. Genomic
DNA (gDNA) and/or total cellular RNA was isolated using
Trizol Reagent (Invitrogen, Karlsruhe, Germany) according
to the manufacturer’s protocol. JAK2 V617F mutation sta-
tus was determined by two different approached using al-
lele-specific (AS)-PCR [1] and PCR restriction fragment
length polymorphism (RFLP) analysis [2] using either the
genomic DNA or complementary DNA (cDNA), synthesized
via reverse transcription of RNA with 200 U MMLV reverse
transcriptase (USB Products, Affimetrix, Cleveland, Ohio,
USA) according to the previously reported method (van
Dongen et al., 1999) [11].
gDNA AS-PCR: Reaction was performed using 100
ngg DNA as a template in a total volume of 25 µl contain-
ing 1x PCR buffer, 1.5 mM MgCl2, 40 pmol of each primer
(control forward primer: 52 -atctatagtcatgctgaaagta-
ggagaaag-32; mutation specific forward primer: 5’-
agcatttggttttaaattatggagtatatt-3’; common reverse primer:
52 -ctgaatagtcctacagtgtttt-cagtttca-32 ) (Baxter et al., 2005)
[12], 200 µM each of deoxynucleoside-52 -triphosphates
(dNTPs), and 1 U of Taq polymerase (Promega, USA). Forty
cycles of amplification were performed with an annealing
temperature of 57°C on a Veriti Thermal Cycler (Applied
Biosystems, Foster City, CA, USA).
gDNA PCR-RFLP: Reaction was performed using
200 nggDNA as a template in a total volume of 32 µl con-
taining 1x PCR buffer, 2.0 mM MgCl2, 40 pmol of each
primer: JAK2 forward primer 5’-gggtttcctcagaacgttga-3’ and
JAK2 reverse primer 5’-tcattgctttcctttttcacaa-3’ (Verstovsek
et al., 2008)[13], 200 µM each of dNTPs, and 1 U of Taq
polymerase (Promega). Forty cycles of amplification were
performed with an annealing temperature of 57°C on a
Thermocycler Rotor-Gene 6000 (Corbett Life Science,
Mortlake, Australia). The amplified fragment was digested
overnight at 37°C with 2 µl BsaXI endonuclease (New Eng-
land BioLabs, Ipswich, MA).
cDNA AS-PCR: Reaction was performed using 2
µl of cDNA as a template in a total volume of 25 µl con-
taining 1x PCR buffer, 1.5 mM MgCl2, 25 pmol mutation
specific forward primer: 5’-agcatttggttttaaattatggagtaggtt-
3’; 25 pmol control forward primer: 5’-gaagatttga-
tatttaatgaaagccttg-3’ and 50 pmol common reverse primer:
52 -ctgaatagtcctacagt-gttttcagtttca-32 , 200 µM dNTPs, and
1 U of Taq polymerase (Promega). Thirty eight cycles of
amplification were performed with an annealing tempera-
ture of 58°C on instructions on a Thermocycler Rotor-Gene
6000 (Corbett Life Science, Mortlake, Australia).
cDNA PCR-RFLP: PCR amplication was carried
out using 4 µl of cDNA as a template in a total volume of
32 µl containing 1x PCR buffer, 1.5 mM MgCl2, 25 pmol
of each primer 5’-taaaggcg-tacgaagagaagtaggagact-3’ and
5’-ggcccatgccaactgtttagc-3’ (Jamieson et al., 2006)[14], 200
µM dNTPs, and 1 U of Taq polymerase (Promega). Thirty
eight cycles of amplification were performed with an an-
nealing temperature of 58°C on a Veriti Thermal Cycler
(Applied Biosystems, Foster City, CA, USA). Following am-
plification, JAK2 amplicons were digested overnight at
37°C with 2 ìLBsaXI endonuclease (New England BioLabs,
Ipswich, MA, USA).
All amplification and digestion products were run
in a conventional 2% (allele-specific PCR) or 3% (PCR
RFLP) agarose gel stained with Sybr Safe (Invitrogen,
Karlsruhe, Germany) and visualized after UV irradiation.
Appropriate controls comprising wild-type, heterozygous
and homozygous JAK2 V617F mutants were included in
all experiments.
The statistical analysis was performed with SPSS
17.0 software.
RESULTS
Demographic data:
The patients with Polycythemia vera (PV) were
26with average age of 55.5 years, between 23 and 75 years.
A small prevalence of the female sex was established
(women: men 54%: 46%).Patients with primary mielo-
fibrozis (PMF) were 16 with an average age of 64 years (44-
74), female: male ratio 40%: 60%.10 patients with essen-
tial trombocitemia (ET) had an average age of 61 years (37-
72), with prevalence of the female sex (women: men –60%:
40%).
JAK2 mutation burden
In the group of patients with PV (26 patients)
JAK2V617F mutation was registered in 81% of cases,   62%
of them were homozigotes and 38% heterozygotes. In the
group of patients with PMF (16 patients) 69% were carri-
ers of the mutation (27% homozigotes and 73% hetero-
zygotes). Among the patients with ET (10 patients) muta-
tion carriers were 60%, as only one patient was homozy-
gote. The distribution according to MPN type is presented
on Fig.1.528 http://www.journal-imab-bg.org / J of IMAB. 2014, vol. 20, issue 4 /
Fig. 1. Myeloproliferative neoplasms (MPNs) and
JAK2V617F mutational burden distribution of the tumor
load in three entities.
Significant positive correlation was found between
MVD and the degree of fibrosis in the bone marrow (r =
0.503, p < 0.0001) as well as between the degree of MVD
and the presence of JAK2 mutation (r = < 0.306, p< 0.002)
in all patient groups (table 1). There was a pronounced sig-
Microvessel density (MVD)
The most significant grade of MVDwas found in the
group of patients with PMF (average MVD 85), followed by
PV (average MVD 70) and ET (average  MVD 52). Kruskal-
Wallis Test showed a statistically significant difference be-
tween the studied groups (p < 0.05), the most distinct be-
tween PMF and PV and PMF and ET (p < 0.01) (fig. 2).
Fig. 2. Bone marrow microvessel density, determined in three groups of malignancies (PV, PLF and ET)
nificant inverse correlation between MVD and bone marrow
cellularity (r =-0.44; p < 0.002). A negative correlation was
found between the presence of JAK2 mutation and the
cellularity in the bone marrow (r =-0.508; p < 0.0001) (table
1)./ J of IMAB. 2014, vol. 20, issue 4 / http://www.journal-imab-bg.org 529
MVDCD34 Fibrosis Cellularity JAK2 Age
Spearman’s MVDCD34 Correlation Coefficient 1.000 .503** * -.440 * * .306 -.105
rho Sig. (2-tailed) . .000 .002 .027 .457
N5 2 48 48 52 52
Fibrosis Correlation Coefficient .503** * 1.000 -.387 * .222 .204
Sig. (2-tailed) .000 . .007 .130 .164
N4 8 4 8 4 8 48 48
cellularity Correlation Coefficient -.440** * -.387 * ** 1.000 -.508 -.097
Sig. (2-tailed) .002 .007 . .000 .514
N4 8 4 8 4 8 48 48
JAK2 Correlation Coefficient .306* * .222 -.508 * 1.000 .124
Sig. (2-tailed) .027 .130 .000 . .380
N5 2 4 8 48 52 52
Age Correlation Coefficient -.105 .204 -.097 .124 1.000
Sig. (2-tailed) .457 .164 .514 .380 .
N 5 24 84 85 2 5 2
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
Table 1. Correlations
DISCUSSION
The constitutive activation of the JAK2/STAT3
signaling pathway has been implicated in events involved
in tumor-host interactions, such as angiogenesis [15]. JAK2/
STAT3 signaling pathway activation mediates tumor angio-
genesis by up-regulation of VEGF and basic fibroblast
growth factor (bFGF) in different carcinoma types [16, 17].
There are only few publications on the relationship between
the existence and the extent of a carrier of JAK2 mutation
and the magnitude of the angiogenesis in the bone marrow
in MPNs. In a study of Tretinski J et al. [18] a significant
increase of angiogenesis in patients with PV and ET was es-
tablished, but there was no correlation with the carrier of
JAK2V617F mutation. In a previous study we have found
that increased angiogenesis is present in all Ph negative
MPNs, in highest degree in PMF [19]. Recently, new genetic
mutations were detected in JAK2V617F negative patients
with MPNs (ASXL1, TET2, DNMT3A, SUZ12, etc.) [20, 21].
However, the role of these mutations in the pathogenesis of
Ph negative MPNs and especially in the initiation and per-
manent stimulation of angiogenesis still remains to be es-
tablished.
CONCLUSIONS
The significant correlation between JAK2V617F, BM
angiogenic activity and the fibrosis marks out the JAK2 al-
lele burden as a feasible parameter with prognostic signifi-
cance for evolution and progression of MPN.
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